StreetInsider.com News Articles

Form 6-K/A NERVGEN PHARMA CORP. For: Aug 13

Fri, 16 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261016/27198297.html

Form 40-F/A NERVGEN PHARMA CORP. For: Dec 31

Fri, 16 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261016/27198286.html

NervGen doses first participant in Phase 3 spinal cord injury trial

Mon, 12 Oct 2026 07:15:13 -0400

NervGen Pharma (NASDAQ: NGEN) announced that the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating its drug candidate NVG-291 in adults with chronic cervical motor-incomplete spinal cord injury.

The multicenter, randomized, double-blind, placebo-controlled study is expected to enroll approximately 150 participants across the United States and Canada. Participants will receive either NVG-291 or placebo via once-daily subcutaneous injection for 12 weeks, followed by a four-week observation period. An optional 12-week open-label extension is planned after study completion.

The study's primary endpoint measures improvement in hand function using GRASSP Quantitative Prehension. Secondary endpoints will assess functional independence and

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

Mon, 12 Oct 2026 07:15:00 -0400

RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury
Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational design
Enrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028

MIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

Mon, 12 Oct 2026 07:15:00 -0400

RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury
Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational design
Enrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028

MIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord

Form 6-K NERVGEN PHARMA CORP. For: Sep 25

Fri, 25 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260925/27107775.html

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

Fri, 25 Sep 2026 16:30:00 -0400

Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.
Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit.

VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced it will restate its audited annual financial statements for the year ended December 31, 2025, and its unaudited interim financial statements for the quarter ended June 30, 2026.

The restatement

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

Fri, 25 Sep 2026 16:30:00 -0400

Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.
Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit.

The restatement

Form 6-K NERVGEN PHARMA CORP. For: Sep 24

Thu, 24 Sep 2026 08:28:00 -0400

si-local-file:///var/storage/secattach/20260924/27099249.html

NervGen to Host Inaugural R&D Day on September 30, 2026

Wed, 09 Sep 2026 07:30:00 -0400

R&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the Phase 3 RESTORE study design and rationale
Four leading experts spanning spinal cord injury clinical care, outcome assessment, translational research and community advocacy to join NervGen management for presentations and a live question-and-answer session
Live webcast on Wednesday, September 30, 2026, beginning at 10:00 a.m. ET

VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage

NervGen to Host Inaugural R&D Day on September 30, 2026

Wed, 09 Sep 2026 07:30:00 -0400

R&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the Phase 3 RESTORE study design and rationale
Four leading experts spanning spinal cord injury clinical care, outcome assessment, translational research and community advocacy to join NervGen management for presentations and a live question-and-answer session
Live webcast on Wednesday, September 30, 2026, beginning at 10:00 a.m. ET

VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage

Form 6-K NERVGEN PHARMA CORP. For: Aug 13

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916517.html

Form 6-K NERVGEN PHARMA CORP. For: Aug 13

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916517.html

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Pharma Corp (NGEN) PT Lowered to $15 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:50 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on NervGen Pharma Corp (NASDAQ: NGEN) to $15.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "We remind investors that NervGen is slated to start patient enrollment near-term in the pivotal RESTORE program of its lead asset NVG-291. In our view, the first patient could be enrolled later this summer. As a reminder, the pivotal RESTORE Phase 3 study is a randomized, double-blind, placebo-controlled trial designed to enroll ~150 adults (18–75) featuring chronic tetraplegia, focused on evaluating efficacy over a 12-week period followed

NervGen Pharma Corp (NGEN) PT Lowered to $15 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:50 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on NervGen Pharma Corp (NASDAQ: NGEN) to $15.00 (from $18.00) while maintaining a Buy rating.

Leerink Starts NervGen Pharma Corp (NGEN) at Outperform

Mon, 13 Jul 2026 06:04:14 -0400

Leerink initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Outperform rating and a price target of $10.00.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click here. For more ratings news on NervGen Pharma Corp click here.

Shares of NervGen Pharma Corp closed at $1.88 yesterday.

Form 6-K NERVGEN PHARMA CORP. For: Jul 02

Thu, 02 Jul 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260702/26729578.html

Form 6-K NERVGEN PHARMA CORP. For: Jul 02

Thu, 02 Jul 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260702/26729578.html

Form SUPPL NERVGEN PHARMA CORP.

Thu, 02 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26729549.html

Form SUPPL NERVGEN PHARMA CORP.

Thu, 02 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26729549.html

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

The analyst comments "NervGen is advancing candidates for the treatment of neurotraumatic and neurologic conditions. Lead asset NVG-291 is set to begin a Ph. III trial in mid-2026 for chronic incomplete tetraplegia, after demonstrated encouraging efficacy in Ph. I/II study. Enrollment is slated to complete mid-2027 with data in early '28. We see our $1.1B peak estimate as achievable given favorable KOL commentary. Buy."

For an analyst ratings summary and ratings history on NervGen Pharma Corp click